Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 13/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 12/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459823 | 1.00 | BCL2L1 (0.44) | BCL2L1MCL1EGFRFLT1FLT4 | |
| SCHEMBL4479046 | 0.87 | ADRB1 (0.49) | BCL2L1MCL1EGFR | |
| SCHEMBL4479050 | 0.87 | ADRB1 (0.49) | BCL2L1MCL1EGFR | |
| SCHEMBL4462043 | 0.77 | MEN1 (0.37) | MEN1LMNAKMT2A | |
| SCHEMBL4462046 | 0.77 | MEN1 (0.37) | MEN1LMNAKMT2A | |
| SCHEMBL4477577 | 0.74 | ADRB3 (0.37) | — | |
| SCHEMBL4477573 | 0.74 | ADRB3 (0.37) | — | |
| SCHEMBL6539107 | 0.72 | MAPT (0.41) | L3MBTL1OPRK1MEN1LMNAKMT2A | |
| SCHEMBL6539110 | 0.72 | MAPT (0.41) | L3MBTL1OPRK1MEN1LMNAKMT2A | |
| SCHEMBL4456304 | 0.72 | ADRB1 (0.42) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | BCL2L1 2463/4885MCL1 4740/4885EGFR 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.